Does the media refer more to ADMA or ANIP?

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 3 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.52 beat ADMA Biologics' score of 0.27 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ANVS or ANIP?

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat ANI Pharmaceuticals' score of 0.52 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANIP or BLTE?

In the previous week, Belite Bio had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 5 mentions for Belite Bio and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Belite Bio's score of 0.20 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ANIP or LNTH?

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANI Pharmaceuticals $883.37M 1.88 $78.34M $4.64 15.56 Lantheus $1.54B 4.23 $233.56M $4.14 24.14

Does the media prefer ANIP or LNTH?

In the previous week, Lantheus had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Lantheus and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Lantheus' score of 0.24 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ANIP or LQDA?

ANI Pharmaceuticals has higher revenue and earnings than Liquidia. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANI Pharmaceuticals $883.37M 1.88 $78.34M $4.64 15.56 Liquidia $158.32M 16.19 -$68.92M $1.37 20.91

Does the media prefer ANIP or LQDA?

In the previous week, Liquidia had 34 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 38 mentions for Liquidia and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Liquidia's score of 0.20 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 7 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral

ANI Pharmaceuticals (ANIP) Competitors

$72.18 -0.78 (-1.07%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$72.76 +0.58 (+0.80%)

As of 10/2/2026 07:58 PM Eastern

Compare

ANIP vs. ADMA, ANVS, BLTE, LNTH, and LQDA

Should you buy ANI Pharmaceuticals stock or one of its competitors? ANI Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), Annovis Bio (ANVS), Belite Bio (BLTE), Lantheus (LNTH), and Liquidia (LQDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 3 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.52 beat ADMA Biologics' score of 0.27 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a net margin of 32.98% compared to ANI Pharmaceuticals' net margin of 11.07%. ADMA Biologics' return on equity of 40.17% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.27	$146.93M	$0.70	13.89
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.56

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 92.04%. ANI Pharmaceuticals has a consensus price target of $98.00, indicating a potential upside of 35.77%. Given ADMA Biologics' stronger consensus rating and higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

ADMA Biologics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats ANI Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Annovis Bio has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 15.9% of Annovis Bio shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat ANI Pharmaceuticals' score of 0.52 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has a net margin of 11.07% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.56

Annovis Bio presently has a consensus price target of $12.00, indicating a potential upside of 912.66%. ANI Pharmaceuticals has a consensus price target of $98.00, indicating a potential upside of 35.77%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

ANI Pharmaceuticals beats Annovis Bio on 11 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Belite Bio?

ANI Pharmaceuticals (NASDAQ:ANIP) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

ANI Pharmaceuticals currently has a consensus target price of $98.00, suggesting a potential upside of 35.77%. Belite Bio has a consensus target price of $218.73, suggesting a potential upside of 37.08%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts plainly believe Belite Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.56
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

ANI Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

In the previous week, Belite Bio had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 5 mentions for Belite Bio and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Belite Bio's score of 0.20 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ANI Pharmaceuticals has a net margin of 11.07% compared to Belite Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Belite Bio	N/A	-11.84%	-11.62%

Summary

ANI Pharmaceuticals beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Lantheus?

ANI Pharmaceuticals (NASDAQ:ANIP) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

ANI Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

In the previous week, Lantheus had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Lantheus and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Lantheus' score of 0.24 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.56
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.14

Lantheus has a net margin of 17.69% compared to ANI Pharmaceuticals' net margin of 11.07%. Lantheus' return on equity of 28.10% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Lantheus	17.69%	28.10%	14.35%

ANI Pharmaceuticals presently has a consensus target price of $98.00, suggesting a potential upside of 35.77%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 8.15%. Given ANI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ANI Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lantheus beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Liquidia?

ANI Pharmaceuticals (NASDAQ:ANIP) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Liquidia has a net margin of 30.74% compared to ANI Pharmaceuticals' net margin of 11.07%. Liquidia's return on equity of 149.65% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Liquidia	30.74%	149.65%	36.30%

ANI Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

ANI Pharmaceuticals presently has a consensus target price of $98.00, indicating a potential upside of 35.77%. Liquidia has a consensus target price of $83.69, indicating a potential upside of 192.22%. Given Liquidia's higher probable upside, analysts clearly believe Liquidia is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Liquidia. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.56
Liquidia	$158.32M	16.19	-$68.92M	$1.37	20.91

In the previous week, Liquidia had 34 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 38 mentions for Liquidia and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Liquidia's score of 0.20 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	7 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Liquidia beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.66B	$12.28B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	15.56	802.26	274.71	26.04
Price / Sales	1.88	940.01	656.46	105.13
Price / Cash	7.27	86.66	78.87	52.62
Price / Book	3.00	10.52	10.93	6.31
Net Income	$78.34M	$2.86B	$3.51B	$362.16M
7 Day Performance	-2.46%	-1.58%	-2.00%	-1.66%
1 Month Performance	1.33%	-5.55%	-6.19%	-4.68%
1 Year Performance	-19.48%	-2.19%	8.03%	1.57%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	4.408 of 5 stars	$72.18 -1.1%	$98.00 +35.8%	-19.5%	$1.66B	$883.37M	15.56	970	Insider Trade
ADMA ADMA Biologics	3.1846 of 5 stars	$9.51 +4.4%	$18.67 +96.3%	-33.7%	$2.04B	$510.17M	13.59	647
ANVS Annovis Bio	2.6895 of 5 stars	$1.19 +3.9%	$12.00 +912.7%	-46.5%	$48.65M	N/A	N/A	7	Positive News
BLTE Belite Bio	3.5002 of 5 stars	$173.40 +1.4%	$218.73 +26.1%	+111.1%	$6.88B	N/A	N/A	41
LNTH Lantheus	3.2512 of 5 stars	$100.28 -0.3%	$108.11 +7.8%	+85.7%	$6.56B	$1.54B	24.22	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, BLTE, LNTH, and LQDA

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Belite Bio?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Summary

How does ANI Pharmaceuticals compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, BLTE, LNTH, and LQDA

How does ANI Pharmaceuticals compare to ADMA Biologics?

Does the media refer more to ADMA or ANIP?

Is ADMA or ANIP more profitable?

Which has better valuation and earnings, ADMA or ANIP?

Do analysts rate ADMA or ANIP?

Which has more risk and volatility, ADMA or ANIP?

Do institutionals and insiders have more ownership in ADMA or ANIP?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Which has more volatility & risk, ANVS or ANIP?

Do insiders & institutionals have more ownership in ANVS or ANIP?

Does the media refer more to ANVS or ANIP?

Is ANVS or ANIP more profitable?

Which has preferable valuation & earnings, ANVS or ANIP?

Do analysts rate ANVS or ANIP?

Summary

How does ANI Pharmaceuticals compare to Belite Bio?

Do analysts prefer ANIP or BLTE?

Do insiders and institutionals have more ownership in ANIP or BLTE?

Which has better earnings & valuation, ANIP or BLTE?

Which has more risk & volatility, ANIP or BLTE?

Does the media prefer ANIP or BLTE?

Is ANIP or BLTE more profitable?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Which has more risk & volatility, ANIP or LNTH?

Does the media prefer ANIP or LNTH?

Which has higher earnings and valuation, ANIP or LNTH?

Is ANIP or LNTH more profitable?

Do analysts rate ANIP or LNTH?

Do insiders & institutionals hold more shares of ANIP or LNTH?

Summary

How does ANI Pharmaceuticals compare to Liquidia?

Is ANIP or LQDA more profitable?

Which has more risk & volatility, ANIP or LQDA?

Do analysts prefer ANIP or LQDA?

Do institutionals & insiders have more ownership in ANIP or LQDA?

Which has preferable valuation and earnings, ANIP or LQDA?

Does the media prefer ANIP or LQDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools